ES
MARKETS / NASDAQ / PRAX
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Praxis Precision Medicines, Inc. PRAX

7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-13.48
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-45.8%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 7-year series below
Revenue Net income
0.00250.0050.00750.010.0-0.3201920222025
0.00250.0050.00750.010.0-0.3201920222025

Per share
USD -13.48
Diluted EPS, FY2025
EPS
0.40.81.2-13.48201920222025
0.40.81.2-13.48201920222025

The company pays no cash dividend.

Profitability
-45.8%
Return on equity, FY2025
ROE
0.250.50.751-45.8%201920222025
0.250.50.751-45.8%201920222025
Operating margin—
Net margin—
Return on assets-42.7%

Each USD of equity lost 46 cents this year.

Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.03B
Shares outstanding, FY2025
0.000.03201920222025
0.000.03201920222025
Change, 5 years—
Change, 10 years—

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 937.9M
total assets, end of FY2025
Total assetsUSD 937.9M
EquityUSD 878.1M
CashUSD 357.3M
Current ratio10.22×

Equity funds 94% of total assets.

History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.0
0.0
0.0
·
·
·
Operating income $B
−0.3
−0.2
−0.1
−0.2
−0.2
−0.1
−0.0
EBITDA $B
−0.3
−0.2
−0.1
−0.2
−0.2
−0.1
−0.0
Income tax $B
0.0
·
·
·
0.0
−0.0
−0.0
Net income $B
−0.3
−0.2
−0.1
−0.2
−0.2
−0.1
−0.0
EPS, diluted $
−13.48
−10.21
−18.69
−69.65
−3.94
−7.86
−26.60
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−45.8
−71.0
−169.1
−130.9
−62.1
−59.9
·
Shares out B
0.03
0.02
0.01
0.00
0.05
0.04
0.00

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed